Advertisement

Picture Berlin Partner Bionnale 2021 Digital Event 650x80px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 3067 | Ordered by Deal: Collaboration or Financing (ascending)
1 2 3 ... 29 30 31  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
10x Genomics–Merck (DE): CRISPR technology, 202006 collab launch integrated solution for CRISPR research 2020-06-10
3SBio–Numab: antibody cancer drug, 201912– collab developm + commercialisation with Sunshine Guojian for multi-specific Abs in Greater China 2019-12-12
4SC–BioNTech: investment, 201604 acquisition €650k of all key operating assets + employees of 4SC Discovery GmbH by new BioNTech Small Molecules GmbH 2016-04-29
4SC–SEVERAL: investment, 201706–201707 cash capital increase €41m with 11.68m new shares at €3.5/share 2017-06-12
4SC–SEVERAL: investment, 201906 capital increase €11m with 4.677m new shares at €2.37/share 2019-06-11
4SC–SEVERAL: investment, 201910–201911 capital increase €22.4m net €22m with 10.65m new shares at €2.1/share with subscription rights 2019-10-07
4SC–Strüngmann Group: investment, 201910 capital increase totalling €22.4m net €22m incl subscription rights for Santo Holding + ATS 2019-10-07
4Teen4 Pharmaceuticals–Brandenburg (govt): investment, 201912 financing round Series A totalling €6.9m incl lead investor Brandenkapital GmbH 2019-12-05
4Teen4 Pharmaceuticals–SEVERAL: investment, 201912 financing round Series A €6.9m led by Brandenkapital GmbH with private investors + business angels 2019-12-05
908 Devices–Manufacturing USA: grant, 201907– grant from NIIMBL for developm of at-line bioreactor process analytics tog w MilliporeSigma et al 2019-07-25
a:head bio–red-stars.com data: investment, 201908– milestone-dependent 7-digit EUR seed investment by red-stars.com data AG in a:head bio AG 2019-08-07
Aadi Bioscience–Helsinn: investment, 201705 financing round Series A totalling $23m incl $2m from co-investor Helsinn Investment Fund 2017-05-08
Aadi Bioscience–SEVERAL: investment, 201705 financing round Series A $23m led by Hermed Capital with Celgene + Vivo Capital + Helsinn et al 2017-05-08
ABAC Therapeutics–SEVERAL: investment, 201802 financing round Series A €16m led by Pontifax + incl GHSF + Caixa Capital Risc + Debiopharm + Ferrer 2018-02-15
Abalos Therapeutics–Boehringer: investment, 201910 financing round Series A totalling €12m invl co-lead investor BIVF 2019-10-15
Abalos Therapeutics–High-Tech Gründerfonds: investment, 201910 financing round Series A totalling €12m incl co-investor HTGF 2019-10-15
Abalos Therapeutics–North-Rhine Westphalia (govt): investment, 201910 financing round Series A totalling €12m incl co-investor NRW.BANK 2019-10-15
Abalos Therapeutics–North-Rhine Westphalia (govt): investment, 201910 financing round Series A totalling €12m incl co-lead investor Gründerfonds Ruhr 2019-10-15
Abalos Therapeutics–SEVERAL: investment, 201910 financing round Series A €12m co-led by BIVF + Gründerfonds Ruhr 2019-10-15
Abalos Therapeutics–Trophic Communications: public relations, 201910 service existent by Trophic 2019-10-15
AbbVie–Apogenix: TRAIL receptor agonists, 201407 aquisition of ww rights to all TRAIL receptor agonists of Apogenix by AbbVie 2014-07-01
Abcalis–Germany (govt): grant, 201912 EXIST research transfer grant for founding from BMWi (plus ESF grant) 2019-12-10
abcr GmbH–Enzymicals: enzymes, 201803– collab distribution expansion ww catalogue sale of selected enzymes + enzyme-produced chemicals 2018-03-01
abcr GmbH–Enzymicals: enzymes, 201903– collab distribution expansion ww sale of all catalogue products of Enzymcials by acbr 2019-03-04
AbeXXa Biologics–Boehringer: investment, 201712 existent investment by BIVF 2017-12-11
ABF–Genedata: bioinformatics, 2013– supply use of Genedata Selector by AB Enzymes for strain genome data management 2013-01-01
ABF–Genedata: bioinformatics, 201707– supply expansion use of Genedata Selector by AB Enzymes for decision support 2017-07-11
Abingworth–SEVERAL: investment, 202102 final closing at $465m of Abingworth Bioventures 8 Fund 2021-02-03
Abionic–SEVERAL: investment, 201808 financing round Series C CHF20m led by P Bottinelli + incl Investiere AG + ZKB + high net worth individuals 2018-03-28
Ablynx–Sanofi: investment, 201801–201806 acquisition recommended cash tender offer €3.9b with €45/share 2018-01-29
AC Immune–Hopp Group: investment, 201812 existent investment dievini Hopp owns 27% of AC Immune SA 2018-12-05
AC Immune–LaVoieHealthScience: public relations, 201909– supply service existent US media relations by LHS 2019-09-20
AC Immune–LifeSci: public relations, 201909 supply service existent European investor + media relations by LifeSci Advisors 2019-09-20
AC Immune–Lilly: credit, 201812 convertible note $50m in connection with license + collab agreement 2018-12-12
AC Immune–Michael J Fox Foundation: grant, 201502 research grant €na for developm of PET tracers for alpha-synuclein protein in Parkinson diagnosis 2015-02-12
AC Immune–SEVERAL: investment, 201605 private financing round Series E CHF42.7m 2016-05-09
AC Immune–SEVERAL: investment, 201609 US IPO $66m net $57.8m net with 6m common shares at $11/share at Nasdaq 2016-09-13
AC Immune–WuXi Pharmatech: biologics contract manfucturing, 201812– collab strategic alliance biologics CDMO with WuXi Biologics 2018-12-19
Acacia Pharma–Gilde Investment: investment, 201103 financing round Series A totalling $10m incl existing investor Gilde Healthcare 2011-03-31
Acacia Pharma–Lundbeck: investment, 201103 financing round Series A totalling $10m incl new investor Lundbeckfond Ventures 2011-03-31
Acacia Pharma–SEVERAL: investment, 201103 financing round Series A $10m from new investor Lundbeckfond Ventures + existing investor Gilde Healthcare 2011-03-31
Accurate Mass Scientific–CovalX: mass spectrometry, 201507– collab AMS new Australian distributor of CovalX High-Mass systems + CRO analytics services 2015-07-15
Acousia Therapeutics–Boehringer: investment, 201805 financing round Series B totalling €10m incl existing + co-investor BIVF 2018-05-14
Acousia Therapeutics–Bregua Corp: investment, 201805 financing round Series B totalling €10m incl new + co-investor Bregua Corp 2018-05-14
Acousia Therapeutics–Creathor Ventures: investment, 201805 financing round Series B totalling €10m incl new + co-investor Creathor Venture 2018-05-14
Acousia Therapeutics–Germany (govt): investment, 201805 financing round Series B totalling €10m incl existing + co-investor KfW 2018-05-14
Acousia Therapeutics–Instinctif Partners: public relations, 201805 service existent by Instinctif 2018-05-14
Acousia Therapeutics–LBBW: investment, 201805 financing round Series B totalling €10m incl lead + new investor LBBW Venture Capital 2018-05-14
Acousia Therapeutics–SEVERAL: investment, 201612 financing round €2.5m led by BIVF + incl KfW + Axxam 2016-12-14
Acousia Therapeutics–SEVERAL: investment, 201805 financing round Series B €10m led by new investor LBBW Venture Capital 2018-05-14
Actelion–Enamine: chemical compound library, 2005– collab supply of screening compound library to Actelion 2005-01-01
Actelion–Enamine: chemical compound library, 201701– collab expansion supply of screening compound library to Actelion 2017-01-23
Actelion–JnJ: investment, 201701–201706 acquisition $30b all-cash tender offer funded w JnJ cash held outside of US 2017-01-26
Actelion–Max Planck: vaccine technology, 201506 license excl synthetic carbohydrate vaccines for new Vaxillion joint venture from + with Max Planck 2015-06-26
Actelion–Reveragen: vamorolone, 201611– excl license option for Actelion 2016-11-03
Acticor Biotech–Merck (DE): rec protein production, 201612– supply Provantage End-to-End Services for developm + manufacturing of Fab 2016-12-05
ActiTrexx–SEVERAL: investment, 202103 financing round Series A €3.5m led by LBBW Venture Capital GmbH 2021-03-02
Active Spectrum–Bruker: investment, 201612 acquisition €na of Active Spectrum by Bruker 2016-12-16
Ada Health–SEVERAL: investment, financing round €40m led by Access Industries (Len Blavatnik) 2017-10-31
Adaptimmune–Ally Bridge Group: investment, 201702 existent investment of ABG 2017-02-23
ADC Therapeutics–Adagene: antibody technology, 201904– collab + license agreem €na using SAFEbody technology for ADC development 2019-04-24
ADC Therapeutics–Deerfield: credit, 202005– convertible credit facility $115m in two conditionable disbursements of $65m + $50m 2020-05-01
ADC Therapeutics–Freenome: pharmacodiagnostics, 201908– collab developm multiomics biomarker for ADCT-402 treatment in DLBCL 2019-08-26
ADC Therapeutics–SEVERAL: investment, 201610 private financing round $105m incl Auven Therapeutics + Wild Family Office + AstraZeneca 2016-10-18
ADC Therapeutics–SEVERAL: investment, 201710 financing round Series E $200m incl Auven Therapeutics + Wild Family Office + AstraZeneca 2017-10-23
ADC Therapeutics–SEVERAL: investment, 201906–201907 financing round Series E expansion $103m bringing total Series E to $303m 2019-06-12
ADC Therapeutics–SEVERAL: investment, 201909–201910 IPO up to approx $230m at NYSE WITHDRAWN 10/19 2019-09-06
ADC Therapeutics–SEVERAL: investment, 202004–202005 IPO at NYSE $267.6m with 14.1m shares at $19/share 2020-04-24
Addex–SEVERAL: investment, 201503 private placement CHF2.8m with 1.53m new shares led by Herculis Partners SA 2015-03-09
Addex–SEVERAL: investment, 201702 private placement CHF3m with 1.5m treasury shares at CHF2/share led by Herculis Partners SA 2017-02-28
Addex–SEVERAL: investment, 201802–201803 private placement CHF40m with 12.78m new shares at CHF3.13/share plus 0.4 warrants at CHF3.43 2018-02-15
Addex–SEVERAL: investment, 201909– filing of Nadaq lisiting of ADSs (without proposing to register any new issuance of secutiries) 2019-09-24
Addex–United States (govt): ADX71441, 201501– collab NIAAA to evaluate ADX71441 in preclinical models of alcohol use disorder 2015-01-07
Adeptrix–Bruker: investment, 202101 financing round Series A incl new + minority investor Bruker Corp 2021-01-06
Adeptrix–SEVERAL: investment, 202101 financing round Series A closed with new + minority investor Bruker Corp 2021-01-06
ADF/IDF–Symrise: investment, 201901– acquisition $900m by Symrise ANNOUNCED 2019-01-31
Adhesys Medical–Grünenthal: investment, 201704 acquisition of Adhesys by Grünenthal 2017-04-07
Adhesys Medical–GSK Stockmann: legal services, 201704 supply legal advisor for sale of Adhesys Medical to Grünenthal 2017-04-07
AdnaGen–Qiagen: investment, 201503 acquisition of assets by Qiagen via newly established Qiagen Hannover GmbH 2015-03-16
Adocia–MC Services: public relations, 201807 service existent PR Europe by MC Services 2018-07-18
Adrenomed–HBM: investment, 201811 financing round Series D totalling €24m incl new + co-lead investor HBM Healthcare Investments 2018-11-26
Adrenomed–HBM: investment, 202011 financing round Series E totalling €22.2m incl existing + co-lead investor HBM Healthcare Investments 2020-11-30
Adrenomed–MC Services: public relations, 201811 service existent by MC Services 2018-11-26
Adrenomed–SEVERAL: investment, 201811 financing round Series D €24m with new + co-lead investors Wellington + HBM plus existing investors 2018-11-26
Adrenomed–SEVERAL: investment, 202011 financing round Series E €22.2m co-led by Wellington Partners + HBM 2020-11-30
Adrenomed–Wellington Partners: investment, 201811 financing round Series D totalling €24m incl new + co-lead investor Wellington Partners 2018-11-26
Adrenomed–Wellington Partners: investment, 202011 financing round Series E totalling €22.2m incl existing + co-lead investor Wellington Partners 2020-11-30
Aduro Biotech–Univ Bonn: cancer immunotherapy, 201704– license for STING agonists via Provendis to Aduro Biotech 2017-04-27
AdvanceCor–Bavaria (govt): investment, 202006 financing round totalling €3.9m incl existing + co-investor Bayern Kapital 2020-06-02
AdvanceCor–First Capital Partner: investment, 202006 financing round totalling €3.9m incl co-investor First Capital Partner 2020-06-02
AdvanceCor–Germany (govt): investment, 202006 financing round totalling €3.9m incl existing + co-investor KfW Bank 2020-06-02
AdvanceCor–MIG Fonds: investment, 202006 financing round totalling €3.9m incl existing + lead investor MIG AG 2020-06-02
AdvanceCor–Occident Group: investment, 202006 financing round totalling €3.9m incl existing + co-investor Occident 2020-06-02
AdvanceCor–SEVERAL: investment, 201805 financing round €6m led by MIG AG + incl Occident Group + Bayern Kapital + HTGF + KfW Bank + founders 2018-05-01
AdvanceCor–SEVERAL: investment, 202006 financing round €3.9m led by MIG AG 2020-06-02
Advanced Accelerator Applications–Novartis: investment, 201710–201801 cash tender offer $3.9b with $41/ordinary share 2017-10-30
AdvanDx–OpGen: investment, 201507 merger acquisition by AdvanDx for 682k shares of OpGen common stock 2015-07-14
AdVita Lifescience–Relief Therapeutics: investment, 202001– binding term sheet acquisition 100% of AdVita for €25m in shares + €20m Milestones 2021-01-20
Aelin Therapeutics–Boehringer: investment, 201712 financing round Series A totalling €27m incl investor BIVF 2017-12-11
Aelin Therapeutics–Flanders (govt): investment, 201712 financing round Series A totalling €27m incl investor PMV 2017-12-11
1 2 3 ... 29 30 31  next pagenext page



Advertisement

Picture BIO Deutschland German Corona Special 2021 Digital 650x80px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [iito] Made Without Love 650x80px

» top